Standard Dose Weekly Intramuscular Beta Interferon-1a May Be Inadequate for Some Patients with Multiple Sclerosis: A 19-Year Clinical Experience Using Twice a Week Dosage-Reference-Cited by-同舟云学术

Standard Dose Weekly Intramuscular Beta Interferon-1a May Be Inadequate for Some Patients with Multiple Sclerosis: A 19-Year Clinical Experience Using Twice a Week Dosage

Published:2022-07-07 Issue:3 Volume:11 Page:1399-1408
ISSN:2193-8253
Container-title:Neurology and Therapy
language:en
Short-container-title:Neurol Ther

Author:

Baumhefner Robert W.^ORCID,Leng Mei

Funder

U.S. Department of Veterans Affairs

Publisher

Springer Science and Business Media LLC

Subject

Neurology (clinical),Neurology

Link

https://link.springer.com/content/pdf/10.1007/s40120-022-00377-1.pdf

Reference26 articles.

1. The IFN beta Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology. 1993;43:655–61.

2. PRISMS Study Group. University of British Columbia MS/MRI Analysis Group. PRISMS-4. Long-term efficacy of interferon beta-1a in relapsing MS. Neurology. 2001;56:1628–36.

3. Schwid SR, Panitch HS. Full results of the evidence of interferon dose-response-European North American comparative efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis. Clin Ther. 2007;29:2031–48.

4. Panitch H, Goodin D, et al. Benefits of high-dose, high-frequency interferon beta-1a in relapsing-remitting multiple sclerosis are sustained to 16 months: final comparative results of the EVIDENCE trial. J Neurol Sci. 2005;239:67–74.

5. Calabrese M, Bernardi V, Atzori M, el al. Effect of disease-modifying drugs on cortical lesions and atrophy in relapsing-remitting multiple sclerosis. Mult Scler. 2012;18:418–24.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Interferon beta-1a sc at 25 years: a mainstay in the treatment of multiple sclerosis over the period of one generation;Expert Review of Clinical Immunology;2023-09-11

2. New insight into brain disease therapy: nanomedicines-crossing blood–brain barrier and extracellular space for drug delivery;Expert Opinion on Drug Delivery;2022-10-31